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The cytokine hypothesis presently suggests that an excessive production of pro-inflammatory cytokines, such as tumour necrosis
factor alpha (TNF) and interleukin 6 (IL6), contributes to the pathogenesis of heart failure. The concept, successfully proved in
genetically modified animal models, failed to translate to humans. Recently, accumulation of apparently paradoxical experimental
data demonstrates that, under certain conditions, production of pro-inflammatory cytokines can initiate the activation of a pro-survival
cardioprotective signalling pathway. This novel path that involves the activation of a transcription factor, signal transducer and
activator of transcription 3 (STAT3), has been termed the survival activating factor enhancement (SAFE) pathway. In this review, we
will discuss whether targeting the SAFE pathway may be considered as a preventive and/or therapeutic measure for the treatment
of heart failure.
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Introduction
In the 1990s, the introduction of the cytokine hypothesis proposed
that an excessive production of pro-inflammatory cytokines con-
tributes to heart failure (HF).1,2 Despite encouraging animal
studies and small clinical trials, larger clinical trials targeting the
cytokines in HF have failed. The question as to whether the
increased levels of inflammatory cytokines observed with HF are
a cause or consequence of the disease still remains unresolved.
In the new millennium, data from numerous animal studies have
lead to a better understanding of the beneficial vs. deleterious
effect of pro-inflammatory cytokines in pathophysiological
conditions. Recent experimental work currently suggests that
activation of these cytokines, including tumour necrosis factor
alpha (TNF) and the interleukin 6 family, can promote a
pro-survival signalling pathway termed the SAFE (survivor activat-
ing factor enhancement) pathway to protect against myocardial
infarction (MI).3,4 In this review, we will summarize evidence for
and against the cytokine hypothesis in both experimental models
and clinical conditions and we will discuss whether targeting the
SAFE pathway may be considered as a preventive and/or thera-
peutic measure for the treatment of HF.
Pro- and anti-inflammatory
cytokines imbalance in heart
failure
Pro-inflammatory cytokines in heart
failure
The interest of TNF (also known as cachectin) inHF evolved from the
observation that cachexia is a common phenomenon associated with
severe HF.5 In the 1990s, numerous studies evidenced an increase in
circulating TNF, function to the severity and the outcome of HF.6,7
The production of TNF in HF may originate from the periphery
(liver) or the myocardium (see review8). In HF patients, cachexia
was associated with a further increase in circulating TNF receptors
type I and type II (TNFR1 and TNR2), through which TNF is believed
to exert its function.6 Tumour necrosis factor receptor type I is
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considered as a major predictor of mortality and new-onset HF in
patients with acute MI (C-ALPHA study).9
The main components of the interleukin 6 family cytokines are
interleukin 6 (IL6), leucaemia inhibitory factor (LIF), and cardiotro-
phin 1. In animal models and in man, these three cytokines are
increased in HF. Similar to TNF, the circulating levels of IL6 increase
with the severity of HF and it may be considered as a prognostic
marker in patients with congestive HF.10,11 The production of IL6
in the disease may originate from either the periphery or the myo-
cardium depending on the disease stage.11,12 In addition to TNF and
IL6, myocardial gene expression of both cardiotrophin 1 and LIF
also increase in the failing heart.13,14 Most of the effects associated
with these cytokines occur after binding to the receptor gp130
which is also increased in HF, to a greater extent in patients with
dilated cardiomyopathy than valvular or ischaemic cardiomyopathy.
This suggests that the role of gp130 in the pathogenesis of chronic
HF may vary as a function of the aetiology of HF.10,14
These studies demonstrate that pro-inflammatory cytokines can
be considered as a biomarker in HF. Unfortunately, levels of cyto-
kines measured from one study to another may vary considerably,
which is related essentially to the commercial kit/technique used
(Table 1).
Anti-inflammatory cytokines in heart
failure
Overall, the production of anti-inflammatory cytokines has been
much less studied than the pro-inflammatory cytokines in the
human heart. The main anti-inflammatory cytokine studied in HF is
interleukin 10 (IL10). Produced in mononuclear cells (essentially
macrophages and T cells), IL10 inhibits the production of
pro-inflammatory cytokines as well as thematrixmetalloproteinases
by activated monocytes.15 Compared with healthy control subjects,
plasma levels of IL10 are decreased in patients with HF, in particular,
in patients suffering from advanced HF NYHA class III and IV.16
Circulating thrombospondin-1, another anti-inflammatory cyto-
kine released upon activation of platelets, is also reduced in HF,
together with tumour growth factor b1.17,18
The cytokine hypothesis: evidence
for and against
Evidence for a contribution of cytokines
in the development and pathogenesis
of the disease
The adverse effect of pro-inflammatory cytokines in the heart has
been widely demonstrated in animal models, using mainly cytokine
depleted or overexpressing mouse models. In experimental
models, inflammatory cytokines promote left ventricular remodel-
ling, acute reversible contractile dysfunction, and uncouple myo-
cardial b-adrenergic receptors (see review19). Cardiac specific
overexpression of TNF causes cardiac failure20 while pathophysio-
logically relevant concentrations of TNF promote progressive left
ventricular dysfunction and remodelling in rats.21 Interleukin 10
knockout animals exhibit increased mortality and larger infarct
size compared with their littermate controls.22 All these data
suggest that limiting the cytokine imbalance observed in pathophy-
siological conditions, such as HF may limit the development of the
disease and improve its outcome. Such modulation of the cytokine
balance in HF can be approached in two ways: (i) by enhancing the
level of anti-inflammatory cytokines and (ii) by targeting a decrease
in pro-inflammatory cytokines. These two approaches have been
considered, to varying degrees, in both experimental models and
clinical conditions.
Increase of anti-inflammatory cytokines
The concept of raising the anti-inflammatory cytokines in HF has
been poorly studied. In animal studies, treatment with recombinant
IL10 limits myocardial lesions in viral myocarditis in rats23 and
improves left ventricular function in rats with HF after experimen-
tal MI.24 This effect was associated with a decrease in circulating
inflammatory cytokines TNF and IL6 and a reduction in myocardial
macrophage infiltration.24 Similarly, chronic treatment with ator-
vastatin increases plasma levels of IL10, decreases the TNF/IL10
ratio, ameliorates left ventricular remodelling, and improves left
ventricular function in rats with HF subsequent to MI.25 In fact,
the simplest and safest way to increase IL10 is with physical exer-
cise. In a rat model of chronic HF, regular swimming improves
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Table 1 Tumour necrosis factor and interleukin 6
levels in various pathophysiological conditions
In humans TNF (pg/mL)
mean
IL6 (pg/mL)
Heart failure (HF)
Ferrari et al.104
(congestive heart
failure)
Control: 14.3+ 7;
HF: 33.5+ 13.1
Milani et al.43 (acute
decompensated
chronic heart
failure)
Control: 0.9+ 0.4;
HF: 3.0+0.4
Testa et al.102
(congestive heart
failure)
Range: 0.5–32 3–300
Petretta et al.103
(mild to severe
CHF)
Class II: 8.3+ 1.0 Class II: 0.7+ 0.7
Class III: 6.0+1.6 Class III: 5.2+1.3
Class IV: 15.0+ 1.1 Class IV: 5.6+1.2
Stumpf et al.16
(chronic heart
failure)
Control: 2.5+ 1.8;
HF: 6.5+2.9
Hirota et al.10
(congestive heart
failure)
Control: 1.7+ 1.6
Class II: 3.8+ 2.0
Class III, IV: 18.5+11.8
Rheumatoid arthritis (RA)
Paramalingam et al.
(2007)
Control: 9; RA : 40 Control: 2; RA: 14
Septic shock (S)
Damas et al.105 471 10049
Charalambos et al.106 With shock: 80+6;
No shock: 61+6
With shock: 266+28;
No shock: 142+28
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plasma levels of IL10 and cardiac function and reduces muscle cel-
lular damage.26
In human studies, specifically targeting an increase of IL10 in HF
has been essentially ignored. Intense treatment with atorvastatin in
patients with stable coronary disease reduces subsequent hospital-
ization for HF.27 Immunomodulation therapy with intravenous
immunoglobulin in patients with chronic HF improved the left
ventricular ejection fraction and increased plasma IL10 levels.28
A recent Cochrane systematic review and meta-analysis shows
that exercise training, known to increase IL10 levels, reduces
HF-related hospitalization and results in clinical improvement in
health-related quality-of-life.29 Similarly, the HF-ACTION study
demonstrates that participation in an exercise training programme
provides improvement in HF patients-reported health status com-
pared with usual care.30 Targeting the anti-inflammatory cytokines
to limit the development of the pathology in HF certainly merits
further investigation.
Decrease of pro-inflammatory cytokines
The concept of decreasing the pro-inflammatory cytokines has
been more readily explored in both clinical and experimental set-
tings but this has led to conflicting and confusing data.
In a viral myocarditis mouse model, anti-TNF improved survival
and myocardial lesions.31 Tumour necrosis factor neutralization
attenuated the impairment of left ventricular function 10 weeks
after MI in rats.32 Similarly, contractile dysfunction was attenuated
in TNF R1 knockout mice with MI33 or with TNF antibodies after
microembolization.34 Conversely, adenoviral transfection of
TNFR1 increased contractile dysfunction following MI.35
In a small randomized preclinical trial with 18 patients of NYHA
class III, a single intravenous infusion of the TNF antagonist Etaner-
cept resulted in a decrease in TNF bioactivity and a significant
overall increase in quality-of-life scores.36 Similarly, pentoxifilline,
a putative TNF inhibitor, was beneficial in small clinical trials with
HF patients. Pentoxyfilline therapy of ischaemic cardiomypathy for
6 months improved the ejection fraction.37 The benefit with regard
to symptoms of HF and cardiac function was seen in all grades of
severity of HF (class I– IV) and in patients with ischaemic and idio-
pathic dilated cardiomyopathy.37,38 However, the beneficial effect
has not consistently been associated with a reduction in
pro-inflammatory cytokines, therefore suggesting that pentoxyfil-
line, which is a phosphodiesterase inhibitor, may protect indepen-
dently of an immunomodulatory effect (see review39).
Diet enriched with omega-3 polyunsaturated fatty acids (v-3
PUFA) may decrease pro-inflammatory cytokines in patients with
HF but further studies are needed to determine the optimal
source and dosing of v-3 PUFA.40
Evidence against a contribution
of cytokines in the disease
In contrast to the preclinical trials, large randomized
placebo-controlled clinical trials with anti-TNF therapies were dis-
appointing. No beneficial effect was observed with Etanercept in
patients with chronic HF (NYHA class II– IV) as reported in
RENEWAL, RENAISSANCE, and RECOVER (see review41). The
ACCLAIM study tested the effect of immunomodulation therapy
in patients with chronic HF. The rationale of the study was to
have a non-specific but broad immunomodulatory effect by redu-
cing pro-inflammatory cytokines and increasing anti-inflammatory
cytokines.42 The trial did not show any significant reduction in
mortality or cardiovascular-related hospitalization. Unfortunately,
the levels of cytokine activation were not assessed in the study.
Of note, two specific sub-group of patients, those without a pre-
vious history of MI and those with NYHA II had significant
reduction in their primary endpoint therefore suggesting that this
therapy may benefit certain subgroups with HF.
The beneficial effect of several drugs in HF also brings into ques-
tion the contribution of pro-inflammatory cytokines in the disease.
In patients hospitalized with advanced acutely decompensated con-
gestive HF, traditional therapy leads to clinical improvement but no
reduction in pro-inflammatory cytokine levels.43 Similarly, treat-
ment with amiodarone in patients with ischaemic cardiomyopathy
is associated with an increase in circulating TNF levels but this
increase is not associated with an adverse effect on survival.44
Although the severity of HF correlates with an increase in
plasma inflammatory cytokines levels in patients, it is important
to mention that these levels are much lower compared with
inflammatory diseases, such as septic conditions (Table 1). Does
this mean that their contribution to the disease, if any, may be rela-
tively modest? Or are there other explanations?
Pro-inflammatory cytokines
initiate a cardioprotective
signalling cascade in the heart:
the survival activating factor
enhancement pathway
With the new millennium, a large body of experimental work con-
ducted in various animal models has brought more insights with
respect to the disappointment of multiple clinical trials targeting
the inflammatory cytokines in HF. In fact, activation of the
immune system (with TNF and/or IL6) can promote the activation
of an intrinsic cell survival signalling pathway that involves acti-
vation of a transcription factor, the signal transducer and activator
of transcription 3 (STAT3). This path, recently discovered in MI,
has been termed the SAFE (survivor activating factor enhance-
ment) pathway.4,45
Tumour necrosis factor and interleukin 6
cytokines can protect against
ischaemia-reperfusion injury
As observed in HF, an increase in pro-inflammatory cytokines
occurs in patients with MI and circulating IL6, TNF, and their
respective receptors are increased further after reperfusion (see
review46). Both cytokines are thought to contribute to contractile
dysfunction,47–50 most likely as a result of perturbation in calcium
homoeostasis and formation of free radicals.51,52
However, as early as 1998, there was experimental data disput-
ing the contribution of TNF or IL6 to the damage associated with
MI. Hence, exogenous addition of TNF protects against hypoxic
injury in cardiomyocytes53 and mice lacking both TNFR1 and
TNFR2 are more susceptible to MI than their littermate controls.54
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Similarly, expression of IL6 occurs in the viable border zone of a
myocardial infarct.55
In fact, the cardioprotective effect of TNF is influenced by
several factors including dose, sex, time, and type of receptors acti-
vated. Hence, TNF protects against ischaemia-reperfusion in a
dose-dependent manner with small amounts of exogenous TNF
(0.5 ng/mL, in vitro) given prior to ischaemia-reperfusion enhancing
cell survival while higher concentrations (10–20 ng/mL, in vitro) are
cytotoxic.3,56,57 Deficiency of TNFR1 protects the myocardium
through IL6 following TNF infusion,58 and the activation of the
TNFR2 seems to convey the protective effect of TNF.59–61
Both cytokines are also important components in the powerful
protective effect of preconditioning, which fails in mice in the
absence of either TNF or IL6.56,62–65 Tumour necrosis factor
can mimic pre- or post-conditioning in vitro and in vivo.47,56,66–68
Signal transducer and activator of
transcription 3 is a downstream target of
tumour necrosis factor and interleukin 6
Once TNF and IL6 bind to their specific receptors (TNFR
and gp130), a common signalling path, called the Janus kinase
(JAK)/STAT3 pathway can be activated (Figure 1). Janus kinases
are a family of tyrosine kinases that are associated with the cyto-
plasmic domain of cytokine and growth factor receptors (including
TNFR and gp130) and play a major role in transducing signals from
the cytosol to the nucleus (see reviews69–71). Upon activation of
the receptors, JAK proteins phosphorylate and create a docking
site for STAT proteins, which in turn are activated by phosphoryl-
ation (Figure 1). While the mechanisms involved in JAK activation
by the gp130 and TNFR1 have been clearly characterized, the acti-
vation of JAK 2 by TNFR2 still remains to be elucidated. Tumour
necrosis factor receptor II does not contain an intrinsic protein
tyrosine kinase but the phosphorylation of JAK2 by this receptor
may occur via TNF receptor-associated factor 2 (TRAF2) or
nuclear factor-kappaB activation, both components previously
implicated in TNF-mediated cardioprotection.72,73 The STAT
family of transcription factor proteins consists of seven identified
members: only STAT3 will be considered in this review. Tyrosine
phosphorylation of STAT3 enables it to homodimerize and trans-
locate to the nucleus. Both tyrosine and serine phosphorylated
STAT3 are also present within the mitochondria.74,75 Under phys-
iological conditions, this pathway can be regulated by the suppres-
sor of cytokine signalling (SOCS) proteins that serve as a negative
regulator of JAK/STAT signalling. Activation of STAT3 induces the
expression of SOCS which in turn binds to the tyrosine 757
residue of membrane receptor which is necessary for the
docking of JAK and STAT3 at the receptors to activate the JAK/
STAT3 pathway (see reviews71,76).
Activation of the SAFE pathway with TNF/JAK/STAT3 or IL6/
JAK/STAT3 signalling is required for the cardioprotective effect
of ischaemic pre- and post-conditioning as neither TNF knockout,
IL6 knockout or cardiomyocyte STAT3 knockout mice could be
protected with a conditioning stimulus.62,63,77–79 Activation of
Figure 1 Survivor activating factor enhancement (SAFE) pathway activated in the heart. After binding onto their specific receptors, tumour
necrosis factor and interleukin 6 family cytokines activate the janus kinase/signal transducer and activator of transcription 3 (JAK/STAT3) signal-
ling path. After phosphorylation, signal transducer and activator of transcription 3 translocates either in the nucleus or in the mitochondria. The
activation of the survivor activating factor enhancement pathway is regulated by the activation of the suppressor of cytokine signalling (SOCS).
Moderate stimulation of the survivor activating factor enhancement pathway leads to cell survival but intense stimulation is detrimental.
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the JAK/STAT3 pathway also occurs with many other cardiopro-
tective agents, such as erythropoietin, cannabinoid agonists,
insulin, prostaglandins, and high density lipoproteins (HDL).4,80,81
Downstream effectors of the SAFE pathway following cytokine
and STAT3 activation still need to be defined. Several targets of
STAT3 have been identified including proteins that are involved
in cell survival and proliferation, such as Bcl-2, Bcl-xL, Mcl-1, Fas,
cyclin D1, E1, p21, some growth factors (VEGF), and other tran-
scription factors (see review4). In the preconditioning setting,
STAT3 plays a critical role by increasing the anti-apoptotic gene
Bcl-2 and reducing the pro-apoptotic gene bax.82 Also, STAT3
mediates cardioprotection via the phosphorylation and inactivation
of the pro-apoptotic factor Bad.64 In late preconditioning, STAT3
activates superoxide dismutase,83 inducible nitric oxide synthase,62
and cyclooxygenase 262 expression. Similarly, the JAK/STAT
pathway protects in opioid-induced cardioprotection via phos-
phorylation and inactivation of glycogen synthase kinase 3b
(GSK3 b).84 Mitochondrial connexion 43, a key element of the
signal transduction cascade of the protection by ischaemic precon-
ditioning,85 may also be a downstream target of STAT3.86
By definition, STAT3 is a transcription factor but its effects
observed in a setting of ischaemia/reperfusion or classic precondi-
tioning do not seem to occur at a transcription level, as the time-
frame between the activation of STAT3 and its action is too short
to allow an effect at the gene level. This observation suggests that
STAT3 has additional effects, such as direct phosphorylation of
target molecules. With the recent discovery that STAT3 translo-
cates to the mitochondria, the protective effect of STAT3 in pre-
and post-conditioning is likely to be mediated by modulating the
opening of the mitochondrial permeability transition pore.75
Tumour necrosis factor can also promote cardioprotection via
TRAF2, nuclear factor kappaB, reactive oxygen species, and
protein kinase C.4,72,73 With regards to sphingolipids, TNF-induced
cardioprotection is mediated via ceramide but sphingosine-1 phos-
phate protects via TNF and STAT3.3,87 Whether these intermedi-
ates form part of the SAFE pathway or constitute an alternative
protective signalling path activated by TNF merits further
investigation.
How to activate the survival activating
factor enhancement pathway?
The SAFE pathway being recently discovered, few upstream targets
have been delineated so far. Initially discovered as a downstream
target of ischaemic preconditioning and ischaemic postcondition-
ing64,67,88 (see Figure 2), it is now recognized that various cardio-
protective agents can activate both TNF and STAT3, such as
bradykinin, adrenoreceptors, leptin, opioids, and cannabinoids.89
Similarly, HDL (whose low levels are associated with poor progno-
sis in patients with HF90) or one of its components sphingosine-1
phosphate, confers protection via the activation of TNF and/or
STAT3.80,87 Moderate consumption of red wine may also confer
cardioprotection via the activation of the SAFE pathway. Hence,
resveratrol and two biogenic amines present in red wine (ethanola-
mine and melatonin) protect the ischaemic isolated mouse heart
against MI but this effect was lost in TNF knockout mice or
STAT3 knockout mice.91,92 Surprisingly, adenosine, a well-known
preconditioning mimetic does not seem to activate the SAFE
pathway, therefore confirming the existence of alternative cardio-
protective signalling paths, such as the well-described reperfusion
injury salvage kinase pathway or protein kinase G-dependent
pathway.63,77,93
Activation of the survival
activating factor enhancement
pathway in heart failure: a safe
therapy to consider?
Evidence for a survival activating factor
enhancement therapy in heart failure
As demonstrated in the previous section, experimental data
provide evidence that activation of the SAFE pathway is protective
in MI, but what about HF?
In humans, the concept that activation of the SAFE pathway may
protect against HF is supported by the alteration in left ventricular
STAT3 and gp130 proteins and phosphorylation of JAK observed
in patients with dilated cardiomyopathy.14,94 The expression of
SOCS is also attenuated in terminally failing human hearts.94 Simi-
larly, women with postpartum cardiomyopathies have a decrease
in STAT3 levels compared with healthy women.95
In experimental studies, although cardiomyocyte STAT3
deficient mice do not develop any cardiac abnormalities of function
or morphology at a young age,96 abnormalities appear with aging
and severe cardiac fibrosis is observed at 6 months (see
review70). Female cardiomyocyte STAT3 deficient mice develop
postpartum cardiomyopathy suggesting that activation of STAT3
is essential to protect the maternal heart from postpartum
oxidative stress.95 Mice with cardiomyocyte overexpression of
STAT3 activate a hypertrophic signal but also a protective signal
against doxorubicin-induced cardiomyopathy by inhibiting
reduction in cardiac contractile gene expression and inducing
cardiac protective factors.97 Similarly, mice with cardiac restriction
of gp130 display rapid onset of dilated cardiomyopathy and massive
Figure 2 Multiple ways of activating the SAFE pathway to
protect against myocardial infarction. SAFE, survivor activating
factor enhancement; HDL, high density lipoprotein cholesterol.
S. Lecour and R.W. James684
induction of myocyte apoptosis during aortic pressure overload vs.
the control mice that exhibit compensatory hypertrophy.98 Also,
activation of STAT3 by granulocyte colony stimulating factor in
dilated cardiomyopathy improves survival and cardiac function.99
Furthermore, activation of gp130/STAT3 with IL11 attenuates
cardiac fibrosis following MI.100
Evidence against a survival activating
factor enhancement therapy
in heart failure
These promising data in favour of a protective effect of the SAFE
activation in HF should however be considered with precaution
for several reasons. First, as mentioned earlier, TNF can activate
two types of receptors, TNFR1 and TNFR2. Activation of the
SAFE pathway involves the activation of TNFR2 only.67 In exper-
imental ischaemic HF, TNFR1 and TNFR2 have disparate and
opposing effects on remodelling, hypertrophy, inflammation and
apoptosis with TNFR1 exacerbating, and TNFR2 ameliorating
these effects.59,61 Potential drugs targeting the activation of the
SAFE pathway should therefore be specific to TNFR2. Second,
continuous gp130-mediated JAK/STAT3 activation obtained by
blockage of the tyrosine 757 on the gp130 site (and therefore inef-
ficacy of SOCS to regulate the pathway) promotes cardiac inflam-
mation, adverse remodelling and HF in mice with MI.101 These data
suggest that an overstimulation of the SAFE pathway would lead to
an adverse outcome. Third, the putative beneficial role of cyto-
kines/STAT3 in ischaemic HF may not translate in non-ischaemic
HF. The kinetics of production of cytokines varies as a function
of the aetiology of HF with, for instance, gp130 increased to a
greater extent in patients with dilated cardiomyopathy than ischae-
mic cardiomyopathy.14 Thus defining beneficial/deleterious roles of
the SAFE pathway in HF will require intensive investigation taking
into account the aetiology of the disease.
Conclusion
In HF, there is an undoubted imbalance between pro-inflammatory
and anti-inflammatory cytokines. This imbalance correlates with
the severity of the disease and the aetiology of HF. Animal
studies conducted essentially on ischaemic HF models with over-
stimulation or repression of the pro-inflammatory cytokines are
in favour of a causal role of these cytokines in the pathogenesis
of HF. In contrast, while human studies suggest that measuring
cytokines can be used as a biomarker for HF, they presently do
not support a contribution of pro-inflammatory cytokines in the
development of the disease. Over the last decade, new experimen-
tal data and human studies have demonstrated the Janus nature of
cytokines, being either cytoprotective or detrimental. It underlines
the dynamic aspect of cytokine action, where questions such as
concentration, the time when produced and the type of receptors
that they activate need to be addressed. The protective effect of
the cytokines has been clearly demonstrated when there is a mod-
erate activation of the SAFE pathway. Conversely, an uncontrolled
activation of the SAFE pathway may be detrimental. Targeting a
controlled activation of the SAFE pathway in HF is undoubtedly
a valid therapeutic objective but the precise kinetic and bioactivity
characteristics of pro-inflammatory cytokines in either chronic or
acute HF should be carefully delineated before this can be
considered.
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